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 24 
Linear ubiquitinylation, a newly identified post-translational modification, is catalyzed by 25 
the linear ubiquitin assembly complex (LUBAC), which is composed of three different 26 
subunits, HOIL-1L, HOIP, and SHARPIN. LUBAC plays a critical role in the activation of 27 
NF-κB signaling triggered by a variety of stimuli, including TNF-α, IL-1β, and 28 
pathogen-derived components, and in the protection from cell death. Loss of function of 29 
SHARPIN in mice triggers chronic inflammation in multiple organs including the skin, as 30 
well as immunodeficiency. In humans, mutations in the gene encoding HOIL-1L cause 31 
chronic hyperinflammation and immunodeficiency, which are both associated with 32 
decreased levels of LUBAC. The linear ubiquitinylation activity of LUBAC is 33 
indispensable for B-cell function in mice, and hyperactivation of LUBAC is associated with 34 
oncogenesis in certain forms of B-cell lymphoma. In this short article, the current 35 
understanding of the biochemistry of LUBAC-mediated linear ubiquitinylation and its 36 
involvement in the immune system are discussed.  37 
38 
































































The ubiquitin conjugation system was identified as a part of an energy dependent 41 
protein degradation system (1-4). However, non-degradable roles of the ubiquitin system 42 
were identified, and ubiquitin conjugation, termed ubiquitinylation, was recognized as a 43 
reversible post-translational modification system that controls the functions of key proteins 44 
involved in various physiological processes, such as protein degradation, cell cycle, 45 
apoptosis, DNA repair, and signal transduction, in all cell types (1, 5-7). Ubiquitin is a 46 
highly conserved 76 amino acid globular protein that is encoded by multiple genes, namely, 47 
two ubiquitin-ribosomal fusion genes and two polyubiquitin genes (8-11). Ubiquitin is 48 
transferred to a lysine residue of a target protein by a cascade of reactions catalyzed by 49 
three types of enzymes, a ubiquitin activating enzyme (E1), a ubiquitin conjugating enzyme 50 
(ubiquitin carrier protein) (E2), and a ubiquitin ligase (E3) in an ATP-dependent manner in 51 
most cases (12-15) (Fig. 1). While conjugation of one ubiquitin to target proteins yields 52 
monoubiquitinylated proteins, the successive attachment of ubiquitin moieties to 53 
ubiquitin-conjugated target proteins results in the generation of polyubiquitinylated proteins. 54 
E3 ubiquitin ligases determine the specificity of ubiquitinylation by recognizing target 55 
proteins, allowing the ubiquitin system to regulate the function of proteins in a timely and 56 
specific manner. Ubiquitin can be conjugated to one of seven Lys residues (K6, K11, K27, 57 
K29, K33, K48, and K63) or to the amino-terminal Met residue (M1) of ubiquitin 58 






























































conjugated to target proteins, yielding several types of polyubiquitin chains (16). The type 59 
of ubiquitin linkage determines the mode of regulation of the protein (17, 18). The K48 60 
chain targets conjugated proteins for degradation, whereas the K63 chain serves as a 61 
specific binding site for the cellular signaling machinery (19, 20). Each type of linkage has 62 
distinct structural flexibility: K48-linked di-ubiquitin forms a relatively compact structure, 63 
and the K63-linked di-ubiquitin adopts a flexible and open conformation. Different 64 
molecular surfaces generated by distinct ubiquitin linkages are specifically recognized by 65 
the corresponding ubiquitin binding domains (UBD) (21, 22) (Fig. 1). Conjugated ubiquitin 66 
molecules are cleaved by deubiquitinylating enzymes (DUBs). More than 90 DUBs exist in 67 
humans, and some DUBs are specific for particular chain linkages (23, 24) (Fig. 1).  68 
This review focuses on a newly identified, M1-linked, linear ubiquitin chain 69 
generated by peptide bond formation between the carboxyl group of the C-terminal glycine 70 
residue (Gly76) of distal ubiquitin moieties and the α-amino group of the Met1 residue of 71 
proximal ubiquitin moieties, and its function in the immune system (25-27). The linear 72 
di-ubiquitin has a relatively open conformation of ubiquitin linkages that resembles that of 73 
K63-linked di-ubiquitin because the position of M1 is close to that of K63 in ubiquitin (16). 74 
Nevertheless, since some UBDs discriminate between the structure of linear and K63 75 
linkages, the linear chain has distinct functions that differ from those of the K63-linked 76 
ubiquitin chain. The linear chain is involved in the activation of nuclear factor-κB (NF-κB) 77 
triggered by various stimuli (28-30). Linear chains also contribute to the regulation of cell 78 






























































death and several pathogenic conditions related to immune cells (31, 32).  79 
 80 
Enzymology of the linear ubiquitin chain  81 
 82 
Among multiple ubiquitin genes, the UBB and UBC polyubiquitin genes encode 83 
polyubiquitin precursors composed of three and nine ubiquitin moieties. However, 84 
translated linear polyubiquitin chains are cleaved into ubiquitin monomers 85 
co-translationally by deubiquitinylating enzymes (33). Indeed, no linear polyubiquitin can 86 
be detected by mass spectrometric analyses, although the presence of ubiquitin linkages via 87 
seven Lys residues in ubiquitin was identified in yeast lacking the enzymes that generate 88 
linear linkages (34). The linear chain and the enzyme that generates it were first identified 89 
in 2006 (27). An E3 ligase complex designated as the linear ubiquitin assembly complex 90 
(LUBAC) is the only identified E3 that generates the linear ubiquitin chain. LUBAC is 91 
composed of three distinct subunits: HOIL-1L (heme-oxidized IRP2 ligase 1L; also known 92 
as RBCK1), HOIP (HOIL-1 interacting protein; also known as RNF31) and SHARPIN 93 
(SHANK-associated RH domain-interacting protein) (26, 35, 36) (Fig. 2).  94 
Both HOIL-1L and HOIP have the RING-IBR-RING (RBR) domain that is a 95 
characteristic feature of ubiquitin ligases; however, only the RBR of HOIP, but not that of 96 
HOIL-1L, is indispensable for the catalytic activity of linear ubiquitinylation (37). The 97 
RBR ubiquitin ligase is part of a newly identified E3 family and thought to be a hybrid type 98 






























































of E3 that is homologous to the E6-AP Carboxyl Terminus (HECT) and Really Interesting 99 
New Gene (RING) ligases reported previously (38). The RING E3 ligase, which serves as a 100 
scaffold for ubiquitin-bound E2 and its substrate, allows the ubiquitin to be directly 101 
transferred from the E2 to the substrate. On the other hand, a ubiquitin moiety is usually 102 
transferred to the conserved cysteine residue of the HECT domain before it is transferred to 103 
a substrate in HECT E3 ligases. The RBR E3 ligase has two RING domains and an 104 
amino-terminal classical RING domain (RING1) within the RBR domain that recognize 105 
ubiquitin-bound E2, as observed in RING ligases; the ubiquitin molecule is then transferred 106 
onto the conserved Cys residue of the RING domain (RING2) to form a thioester 107 
intermediate, and ubiquitin bound to the conserved Cys residue is transferred onto a 108 
substrate (Fig. 3). Thus, the specificity of ubiquitin linkages is thought to be dependent on 109 
the final state of the thioester intermediate, namely, by the RBR E3. Indeed, LUBAC 110 
specifically generates the linear ubiquitin linkage regardless of the E2s (27) and RING2, 111 
and the linear ubiquitin chain determining domain (LDD) is involved in the linkage 112 
specificity (39).  113 
HOIL-1L and SHARPIN are accessory molecules that are involved in the 114 
stabilization of LUBAC. In cells lacking HOIL-1L or SHARPIN, the other two components 115 
of LUBAC are rapidly degraded via an unknown mechanism, leading to a significant 116 
decrease in the ability for linear ubiquitinylation (25, 26). Interactions between the 117 
ubiquitin-like (UBL) domain of HOIL-1L and ubiquitin-associated (UBA) domain of HOIP 118 






























































play a role in the formation of the LUBAC complex, as confirmed by crystallographic 119 
analysis of the complex composed of the UBL domain of HOIL-1L and UBA-containing 120 
HOIP (40). Interactions between HOIP Npl4-type zinc finger/RanBP2 zinc finger (NZF) 2 121 
and SHARPIN UBL are also involved in LUBAC formation (41, 42); however, HOIP 122 
lacking NZF2, and not UBA, can bind to SHARPIN in cells (26). If the two accessory 123 
molecules are absent, the ligase activity of HOIP is lost almost completely because of the 124 
auto-inhibitory effect of the N-terminal region of HOIP containing UBA domain (41). Thus, 125 
HOIL-1L and SHARPIN play crucial roles in enhancing the activity of LUBAC. The 126 
molecular weight of LUBAC was estimated at 600 kDa by gel filtration analyses, although 127 
HOIL-1L, HOIP, and SHARPIN are 58 kDa, 120 kDa, and 40 kDa, respectively (26, 27) 128 
(Fig. 2). Thus, the LUBAC complex is thought to contain at least two or three HOIP 129 
components, although the precise subunit composition of the complex remains unknown. It 130 
is awaiting the resolution of the intact crystal structure of the whole ternary complex of 131 
LUBAC. 132 
In cells, ubiquitin conjugation to target proteins must be regulated spatially and 133 
temporally and induced only when needed. Ubiquitin chains generated in response to 134 
various stimuli are recognized by proteins that have specific UBDs to exert their function. 135 
The ubiquitin chains are eventually cleaved by DUBs to abrogate the functions associated 136 
with each chain (23, 43). DUBs cleave peptide or isopeptide bonds between ubiquitin and 137 
the substrate, and between ubiquitin molecules (inter-ubiquitin linkage) to dissociate 138 






























































ubiquitin from substrates or ubiquitin, leading to the elimination of the activated state. 139 
Some linkage-specific DUBs have been reported, and two DUBs, an ovarian tumor (OTU) 140 
DUB with linear linkage specificity (OTULIN, also termed Fam105b or Gumby) and 141 
cylindromatosis (CYLD), were shown to cleave linear ubiquitin linkages (44-46). The K63 142 
position is very close to the M1 of ubiquitin, and structural analyses revealed that linear and 143 
K63 di-ubiquitins are structurally very similar (47, 48). However, OTULIN binds 144 
preferentially to linear di-ubiquitin compared to K63 di-ubiquitin (approximately 100-fold 145 
higher affinity for the former) and selectively cleaves linear ubiquitin linkages (45). 146 
Another DUB, CYLD, can digest linear linkages. CYLD, which was identified as a tumor 147 
suppressor commonly mutated in familial cylindromatosis, is involved in the regulation of 148 
NF-κB activation and was shown to cleave K63 chains specifically (49-53). However, 149 
CYLD can digest linear linkages in addition to the K63 linkage, as the structure of the K63 150 
chain is similar to that of linear di-ubiquitin (46). 151 
     152 
Mice lacking LUBAC subunits or linear chain specific DUBs  153 
 154 
Many combinations of E2s and E3s can generate the same ubiquitin linkages. For 155 
example, an E2 complex containing Ubc13 generates K63 chains specifically together with 156 
multiple E3s. However, in the case of linear chains, LUBAC is the only E3 identified to 157 
date that generates linear chains together with multiple E2s. Thus, the function of linear 158 






























































chains could be probed by ablating the activity of LUBAC. However, phenotypes provoked 159 
by ablation of subunits of LUBAC, HOIP, HOIL-1L, and SHARPIN are very much 160 
different. First, we describe phenotypes of mice lacking subunits of LUBAC and two DUBs 161 
that cleave linear linkages. We then discuss the in vivo roles of these molecules in the 162 
immune system. 163 
 164 
a) HOIP 165 
 166 
Among the three subunits of LUBAC, HOIP is the catalytic subunit. Therefore, 167 
we first describe results obtained with mice having genetically engineered HOIP loci. Mice 168 
lacking the catalytic activity of HOIP were shown to be embryonic lethal, although a 169 
precise phenotype was not described yet (54). The HOIP
-/-
 mouse phenotype was reported 170 
recently. HOIP
-/-
 mice die at approximately E10.5 and show disrupted vasculature in the 171 
yolk sac (55). This appears to be caused by increased endothelial cell death. Because of its 172 
lethality, the function of linear ubiquitin in the immune system could not be addressed 173 
without using conditional knockout (KO) mice. Analyses using conditional KO mice are 174 
discussed later.  175 
 176 
b) SHARPIN 177 
 178 






























































Mice lacking another subunit of LUBAC, SHARPIN, exhibit different 179 
phenotypes. Spontaneous autosomal recessive mutant mice, called chronic dermatitis in 180 
mice (cpdm), were identified in 1993 as mice exhibiting chronic dermatitis (56). In 2007, 181 
SHARPIN was identified as a causative gene product in these mice (26, 35, 36). Two 182 










both of which have a mutation in the first exon resulting in a frame-shift and the absence of 185 
functional SHARPIN proteins (56). Because of the lack of SHARPIN, the amounts of the 186 
remaining two components of LUBAC, HOIL-1L and HOIP, are drastically reduced, which 187 
markedly decreases linear ubiquitinylation activity although the ligase activity of LUBAC 188 
is not completely lost. The characteristic phenotype of both strains of mice is severe 189 
chronic inflammation of the skin starting at 5–6 weeks after birth. The skin lesions are 190 
identified by epidermal hyperplasia, hyperkeratosis, parakeratosis, scattered apoptotic or 191 
necrotic cell death of keratinocytes, and infiltration of granulocytes, macrophages, and mast 192 
cells in the dermis and the epidermis (57-60). The development of dermatitis is thought to 193 





 double mutant mice, which lack T and B cells, show a similar 195 
phenotype to that of SHARPIN
cpdm-Dem
 mice (61). In addition to the dermatitis, infiltration 196 
of neutrophils and macrophages is also seen in multiple organs such as the lung, liver, and 197 
several joints. The mice also show structural defects of secondary lymphoid organs, 198 






























































splenomegaly, a disrupted marginal zone in the spleen, the absence of Peyer’s patches in 199 
the adult intestine, and reduced levels of serum IgG, IgA, and IgE, but not IgM, which 200 
indicates defective class switching in B cells (62, 63).  201 
When cpdm mice are crossed with TNFα
-/-
 mice, the dermatitis, but not the 202 
systemic inflammatory effects on other organs, of cpdm mice are drastically rescued, even 203 
though they carry a heteroallelic deletion of TNF-α (36). Moreover, intercrossing cpdm 204 
mice with RIP1 kinase dead mice cures the cpdm symptoms almost completely (64). The 205 
upregulation of HOIP and HOIL-1L in the skin also ameliorates cpdm mice and attenuates 206 
NF-κB activation. Thus, a reduction of LUBAC, and thereby of linear ubiquitinylation 207 
activity, associated with the loss of function of SHARPIN and its effects on inhibiting 208 
NF-κB and promoting cell death underlie the pathogenesis of cpdm mice. 209 
 210 
c) HOIL-1L 211 
 212 
 Loss of HOIL-1L in mice has also been reported (25). Loss of HOIL-1L 213 
destabilizes the other two components of LUBAC and reduces the linear ubiquitinylation 214 
activity of LUBAC. Signal-induced NF-κB activation is attenuated; however, HOIL-1L KO 215 
mice do not exhibit overt phenotypes. This can be attributed to the fact that lack of 216 
HOIL-1L enhances cell death only marginally.   217 
 218 






























































d) OTULIN 219 
 220 
Homozygous mutant mice carrying a mutation in OTULIN (W96R) called gumby 221 
mice, which exhibit virtually no DUB activity (65), die at E10.5 and show defects in the 222 
organization of branching vascular networks in the head and trunk. Linear ubiquitinylated 223 
proteins accumulate in gumby embryos compared to control embryos (65). The Wnt 224 
signaling pathway, which is essential for the sprouting of blood vessels from the 225 
pre-existing vasculature during angiogenesis, is activated in gumby mice because of 226 
impaired linear DUB activity. Indeed, OTULIN interacts with disheveled 2 (DVL2), a 227 
critical protein involved in the canonical Wnt pathway, and suppresses canonical Wnt 228 
signaling in overexpression studies (46).   229 
 230 
f) CYLD 231 
 232 
Since CYLD can cleave K63 in addition to linear linkages, its functions are not 233 
defined by the cleavage of linear chains alone. Familial cylindromatosis, of which CYLD is 234 
a causative gene product, is characterized by multiple benign tumors that develop from skin 235 
appendages, such as hair follicles and sweat glands (49, 66, 67). In animal models, CYLD
-/-
 236 
mice do not develop spontaneous tumors; however, they are highly susceptible to dextran 237 
sulfate sodium (DSS)-induced colitis and azoxymethane (AOM)-induced tumor 238 






























































development (68, 69). Thus, CYLD plays a critical role in the suppression of tumor 239 
proliferation (53). Overexpression of CYLD leads to a decrease in NF-κB activity induced 240 
by several receptors including TNFR1, CD40, TLR4, EDAR, and LMP1 (51, 70). 241 
Moreover, CYLD interacts with TNFR1-associated factor (TRAF)2 and TRAF6 and 242 
impairs their linear ubiquitinylation via its deubiquitinylating activity (51). In addition, 243 
CYLD was suggested to be involved in the induction of cell death (71-75). 244 
 245 
Mechanistic insight into the functions of linear ubiquitinylation 246 
 247 
Next we discuss the function of linear ubiquitin chains. Accumulating evidence 248 
supports the involvement of linear ubiquitin chains in canonical NF-κB activation and the 249 
regulation of cell death. Here, we summarize current knowledge on the molecular 250 
mechanisms underlying canonical NF-κB activation and cell death regulation mediated by 251 
linear ubiquitinylation. Other functions of linear ubiquitin chains are also discussed.  252 
 253 
a) NF-κB activation 254 
 255 
The first identified function of the linear ubiquitin chain was its involvement in 256 
the activation of the canonical NF-κB pathway. NF-κB is a member of a family of dimeric 257 
transcription factors composed of five Rel homology domain (RHD)-containing proteins, 258 






























































including RelA (p65), RelB, c-Rel, p105/p50 (NF-κB1), and p100/p52 (NF-κB2). The 259 
RHD in the amino-terminal region is required for dimerization, nuclear import, and binding 260 
to 9–10 base pair NF-κB-responsive elements referred to as κB sites. NF-κB is involved in 261 
various biological processes including immune responses, inflammation, and cell survival. 262 
Aberrant activation of NF-κB plays a role in immunological disorders and oncogenesis, 263 
including some forms of B-cell lymphoma (76, 77). Two NF-κB activation pathways have 264 
been described, the canonical (classical) and alternative (non-canonical) pathways, which 265 
have distinct physiological consequences (78-80). Here, the canonical pathway is 266 
introduced because LUBAC-mediated linear ubiquitinylation is involved in the canonical 267 
but not the alternative pathway (25, 26, 54) (Fig. 4). Various ligands induce the activation 268 
of the canonical NF-κB pathway, which is associated with local inflammatory and immune 269 
responses. In the resting state, NF-κB is restrained in the cytoplasm through binding to 270 
inhibitor of NF-κB (IκB) proteins. IκBs, which include IκBα, IκBβ, and IκBε, associate 271 
with the RHDs of NF-κB via their ankyrin-repeat motif. The IκB kinase (IKK) complex is 272 
composed of IKK1 (IKKα), IKK2 (IKKβ), and NF-κB essential modulator (NEMO; also 273 
called IKKγ), and is a critical mediator of the canonical NF-κB pathway (78, 79, 81). Upon 274 
activation by various stimuli, the IKK complex is activated by phosphorylation of specific 275 
serine residues on IKK2 and induces the phosphorylation of IκBs. Phosphorylated IκBs are 276 
recognized by the SCF
βTrCP
 ubiquitin ligase, followed by K48-linked ubiquitinylation and 277 
degradation via the proteasome (82-85) (Fig. 4). LUBAC plays a role in the canonical 278 






























































NF-κB pathway triggered by TNF-α, IL-1β, CD40 ligand (CD40L), and certain Toll-like 279 
receptors (TLRs) (25, 35, 54). The current hypothesis for the role of LUBAC-mediated 280 
linear ubiquitinylation in canonical NF-κB activation triggered by ligands of the TNFR 281 
family is as follows: upon activation by various stimuli, LUBAC preferentially recognizes 282 
and conjugates linear ubiquitin chains on NEMO (25, 86). Mutational analysis revealed that 283 
the interaction between the NZF1 domain of HOIP and the coiled-coil 2 and leucine zipper 284 
(CoZi) domains of NEMO is involved in LUBAC-mediated linear ubiquitinylation at 285 
Lys285 and Lys309 in the CoZi domain of NEMO (25). NEMO possesses a specific 286 
ubiquitin binding region referred to as the ubiquitin binding in ABIN and NEMO (UBAN) 287 
motif within the CoZi domain (87). The UBAN motif has high affinity for linear 288 
di-ubiquitin, but not for K63 di-ubiquitin chains (87, 88). Recognition of the linear 289 
di-ubiquitin conjugated to NEMO by the UBAN domain of another NEMO in trans may 290 
trigger dimerization of the IKK complex, and subsequent trans-autophosphorylation of two 291 
specific Ser residues of IKK2, because amino acid residues in the kinase domain of IKK2 292 
involved in IKK2 dimerization are required for IKK2 phosphorylation (89) (Fig. 4). Upon 293 
activation by various stimuli, recognition of NEMO conjugated linear ubiquitin chains by 294 
the UBAN domain of NEMO, which is specific for the linear chain, triggers NF-κB 295 
activation. Thus, DUBs that cleave linear chains are thought to block the signal generated 296 
by conjugation of linear ubiquitin chains. Recently, two DUBs, OTULIN and CYLD, which 297 
can cleave linear chains, were shown to bind continuously to LUBAC via the peptide 298 






























































N-glycosidase (PNGase)/ubiquitin-associated (PUB) domain of HOIP (46, 90, 91). The 299 
ligase-DUB interaction is not regulated by any stimulus (46). The activation of NF-κB by 300 
TNF-α is intensified in HOIP null cells expressing a HOIP mutant that is unable to interact 301 
with OTULIN or CYLD compared to that in cells expressing wild-type HOIP. Thus, the 302 
ligase-DUB interaction may play a role in the optimization of the strength of the signal 303 
initiated by stimuli, possibly by modulating the length or number of linear ubiquitin chains. 304 
Phosphorylation of a Tyr esidue in the PUB-interacting motif of OTULIN abolishes the 305 
interaction between the two proteins (90, 91); therefore, signaling mediated by linear chains 306 
might be modulated by the activation of tyrosine kinases. The precise role of the interaction 307 
between LUBAC and the two DUBs remains to be elucidated.  308 
Another DUB, A20, is involved in the suppression of linear chain-mediated 309 
NF-κB activation, although it functions in a DUB-independent manner (92, 93). A20, 310 
identified as a suppressive factor for NF-κB signaling upon TNFR and TLR stimulation (94, 311 
95), contains seven Cys2-Cys2 zinc finger (ZF) repeats in the carboxyl-terminal region in 312 
addition to the N-terminal OTU domain. A20 attenuates NF-κB activation by cleaving K63 313 
chains on RIP1 and conjugating K48 chains onto RIP1, leading to the degradation of the 314 
kinase (95). A20 was also shown to suppress LUBAC-mediated NF-κB activation via the 315 
linear chain specific binding activity of the seventh zinc finger (ZF7), possibly by 316 
preventing the recruitment of LUBAC and NEMO to the activated receptor complex (92, 317 
96). Considering that A20 is a target of NF-κB and rapidly induced after stimulation, it may 318 






























































be a key factor in a negative feedback loop modulating NF-κB-induced gene expression.  319 
Linear ubiquitinylation is also involved in NF-κB activation via the 320 
nucleotide-binding oligomerization domain-containing (NOD)-like receptors (NLRs) NOD 321 
1 and 2, which are cytoplasmic pattern recognition receptors (PRRs) (97, 98). NOD1 and 322 
NOD2 selectively recognize bacterial PGN found in both gram-positive and gram-negative 323 
bacteria. NOD receptor signaling is initiated by the interaction between NODs and RIP2, 324 
which is mediated by the homotypic interaction between their caspase recruitment domains 325 
(CARDs). The baculovirus IAP repeat 2 (BIR2) domain of RIP2 then recruits X-linked IAP 326 
(XIAP), an E3 ligase with a RING domain, which ubiquitinates RIP2 leading to NF-κB 327 
activation (97). Although RIP2 is modified by K63 polyubiquitinylation in NODs signaling, 328 
the ligase activity of LUBAC is also involved in NOD2-mediated NF-κB activation. The 329 
dependence of the interaction between LUBAC and the NOD signaling complex on the 330 
ubiquitin ligase activity of XIAP suggests that LUBAC is recruited to the NOD signaling 331 
complex via recognition of XIAP-generated ubiquitin chains. The major linear 332 
ubiquitinylated protein involved in NOD signaling is RIP2. NOD2 signaling is also limited 333 
by OTULIN via cleavage of RIP2-conjugating linear ubiquitin chains. Accordingly, 334 
deletion of OTULIN increases the linear ubiquitinylation of RIP2 in response to NOD2 335 
stimulation. However, the role of the linear ubiquitinylation of RIP2 in NOD2 signaling 336 
remains unknown. NEMO might also be ubiquitinylated in this setting and involved in 337 
NF-κB activation, despite the fact that NEMO ubiquitinylation has not been convincingly 338 






























































detected (99).   339 
 Linear ubiquitinylation is also involved in canonical NF-κB activation mediated 340 
by membrane PRRs, TLRs. TLR ligand-induced canonical NF-κB activation is mediated by 341 
Myd88 (100, 101). Upon stimulation with TLR ligands, Myd88 is recruited to activated 342 
TLRs, followed by recruitment of the TRAF6 ubiquitin ligase. K63 chains generated by 343 
TRAF6 on TRAF6 itself or on other proteins in the activated receptor complex may 344 
function as a recruitment signal for LUBAC and induce NF-κB activation. Linear 345 
ubiquitinylation is also involved in IL-1β-mediated NF-κB activation, in which Myd88 also 346 
plays a role, since linear ubiquitinylation of NEMO was detected in cells stimulated with 347 
IL-1β (25). However, residual NF-κB activation in cells lacking linear ubiquitinylation 348 
activity differs among stimuli and cells: IL-1β-mediated NF-κB activation in mouse 349 
embryonic fibroblasts (MEFs) is more severely suppressed than that mediated by TLR9 350 
ligands in B cells lacking LUBAC’s ligase activity (54). Moreover, LUBAC-mediated 351 
linear ubiquitinylation is dispensable for NF-κB activation induced by B-cell antigen 352 
receptor, although CD40-mediated NF-κB activation is impaired almost completely in B 353 
cells lacking the catalytic center of HOIP (54). In addition, a ligase-independent role of 354 
LUBAC in NF-κB activation was suggested (102). Thus, current results indicate the 355 
existence of several pathways for the activation of IKK.  356 
The involvement of another polyubiquitin chain, the K63-ubiquitin chain, in 357 
NF-κB activation was also suggested (29, 103, 104). In this scenario, K63 chains function 358 






























































as platforms to recruit both IKK and the TAK1 complex, which is composed of TAK1, 359 
TAB1, and TAB2 and/or TAB3, via the ubiquitin binding activities of NEMO and TAB2 360 
and/or TAB3, respectively. Then, the TAK1 kinase phosphorylates IKK2, leading to IKK 361 
activation. However, since binding of NEMO to K63 is weak because the UBAN domain of 362 
NEMO prefers linear di-ubiquitin to K63 di-ubiquitin (87), K63 chains alone may not be 363 
enough to activate IKK. Recently, mixed ubiquitin chains, in which both linear and K63 364 
linkages co-exist, were identified (105). The TAK1/TAB2/TAB3 and the IKK complex can 365 
be recruited to the mixed chain via K63 and linear ubiquitin binding activities, respectively 366 
(106). This leads to the phosphorylation of the Ser residues of IKK2 by TAK1 and by 367 
trans-autophosphorylation induced by linear chains (89). Linear ubiquitin chains appear to 368 
play central roles in canonical NF-κB activation induced by ligands of the TNF receptor 369 
family; however, further analyses are necessary to clarify the roles of linear ubiquitin 370 
chains in IKK activation completely. abolishes 371 
 372 
b) ERK activation.  373 
 374 
In addition to their involvement in NF-κB activation, linear chains play a role in 375 
ERK activation (54). In B cells and macrophages, IKK activates ERK via TPL2 376 
phosphorylation (107, 108). Loss of the linear ubiquitinylation activity of LUBAC 377 
abolishes CD40- and TLR-mediated ERK activation in B cells almost completely (54). 378 






























































Thus, linear ubiquitinylation plays a role in ERK activation through IKK, which is 379 
activated by linearly polyubiquitinylated NEMO (54). However, B-cell receptor 380 
(BCR)-mediated ERK activation is not overtly affected in B cells lacking the catalytic 381 
center of HOIP, indicating that multiple ERK activation pathways exist in B cells (54). 382 
 383 
c) Cell death regulation 384 
 385 
Certain TNFR family receptors such as TNF receptor 1 (TNFR1) trigger cell 386 
death signals, and LUBAC-mediated linear ubiquitinylation is involved in the regulation of 387 
TNFR1-mediated cell death; however, the linearly ubiquitinylated substrates involved in 388 
cell death regulation remain to be identified (36, 109, 110). TNFR1 is constitutively 389 
expressed on the surface of almost all cell types and plays a role in immune and 390 
inflammatory responses during infection, cell proliferation, and the regulation of the 391 
programmed cell death processes known as apoptosis and necroptosis (programmed 392 
necrosis). TNF-α and lymphotoxin alpha (LT-α, also referred to as TNF-β) are the ligands 393 
of the receptor. Activation of TNFR1 is initiated by its trimerization on the cellular 394 
membrane in response to the binding of extracellular ligands. This leads to a 395 
conformational change in the intracellular death domain (DD) of TNFR1 that results in the 396 
recruitment of two DD-containing adaptor proteins, TNFR-associated death domain 397 
(TRADD) and receptor interacting protein 1 (RIP1), through direct interaction between the 398 






























































DDs (Fig. 4). Certain ubiquitin E3 ligases such as TRAF2, and cellular inhibitor of 399 
apoptosis protein 1 and 2 (cIAP1, 2) are recruited to activated TNFR1 via TRADD to 400 
assemble a signaling complex known as complex I at the cell membrane (111, 112). In 401 
addition to the known components of complex I, LUBAC is also recruited to the activated 402 
TNFR1 complex (113). The recruitment of LUBAC to the TNFR1 signaling complex is 403 
dependent on the ubiquitin ligase activity of cIAP1 and cIAP2. The NZF domains are 404 
UBDs, and the HOIP NZF1 domain can recognize ubiquitin and NEMO simultaneously 405 
(89). The ubiquitin binding activity of the NZF1 domain of HOIP is critical for the 406 
recruitment of LUBAC to the activated TNF receptor complex and possibly functions by 407 
recognizing ubiquitin chains conjugated by cIAPs (Fig. 5) (113). cIAPs ubiquitinylate not 408 
only the components of the TNFR1 signaling complex including RIP1, but also undergo 409 
auto-ubiquitinylation, eventually leading to the generation of high amounts of various types 410 
of ubiquitin chains, including K63 chains. Recognition of K63 chains by HOIP NZF1 may 411 
be involved in the recruitment of LUBAC to the activated TNFR1 complex (113). 412 
K11-linked chains generated by cIAPs are involved in canonical NF-κB activation, 413 
suggesting that the HOIP NZF binds to K11 chains, although this has not been definitely 414 
proven (114). The recruitment of LUBAC to the activated TNFR1 complex may lead to the 415 
recruitment of IKK and the linear ubiquitinylation of NEMO, resulting in the activation of 416 
NF-κB.   417 
The linear ubiquitinylation activity of LUBAC is required for the protection of 418 






























































cells from TNF-α-mediated cell death. LUBAC can induce the expression of anti-apoptotic 419 
genes including Bcl2 and cFLIP by activating NF-κB. In addition, LUBAC inhibits 420 
TNF-α-mediated cell death by a different mechanism. The transition from complex I to 421 
complex II triggers cell death. TNFR1 induces two types of programmed cell death, 422 
apoptosis and necroptosis, both of which can be initiated by the formation of complex II, 423 
which is composed of TRADD, FADD, caspase 8, RIP1, and possibly RIP3 (Fig. 5). 424 
Caspase 8 is activated by dimerization and digests RIP1 and RIP3, leading to apoptosis. 425 
When caspase 8 is inactivated, RIP1 and RIP3 kinases are activated by trans- or 426 
auto-phosphorylation, which triggers necroptosis (115-117). The linear ubiquitinylation 427 
activity of LUBAC plays a role in suppressing the formation of complex II, although the 428 
linear ubiquitinylation substrates involved in the inhibition of complex II formation have 429 
not been convincingly identified yet (36). The removal of K63 linked chains by the A20 or 430 
CYLD DUBs from RIP1 is involved in complex II formation (95, 118-121). However, 431 
RIP1 is modified by multiple types of chains, including K11 and linear chains in addition to 432 
K63 chains. Considering that the linear ubiquitinylation activity of LUBAC is required for 433 
the inhibition of complex II formation, the linear ubiquitinylation of RIP1 might be 434 
involved in the inhibition of TNF-α mediated cell death by LUBAC. However, further 435 
analyses are needed to clarify the role of LUBAC-mediated linear ubiquitinylation in cell 436 
death regulation. 437 
 438 






























































d) Other functions  439 
 440 
The involvement of LUBAC-mediated linear ubiquitinylation in other functions 441 
was investigated using HOIL-1L
-/-
 or cpdm mice.  442 
  443 
d)-1 Regulation of inflammasome formation 444 
 445 
Pyrin domain-containing 3 (NLRP3), an NLR, functions in the assembly of the 446 
inflammasome, which promotes the production of proinflammatory cytokines, mainly 447 
IL-1β and IL-18 (122, 123). NLRP3 senses several pathogen-associated molecular patterns 448 
(PAMPs) as well as host damage-associated molecular patterns (DAMPs) released from 449 
injured and necrotic cells. The activated NLRP3 and the adaptor protein ASC act together 450 
to assemble the inflammasome, which potentiates the cleavage of pro-caspase 1, followed 451 
by the release of two active forms, the p10 and p20 domain-containing subunits. The 452 
resultant active caspase 1 cleaves pro-IL-1β and pro-IL-18 to generate the mature 453 
proinflammatory cytokines. Thus, NLRP3 is involved in innate immune responses through 454 
the rapid production of IL-1β and IL-18. Formation of the NLRP3-ASC inflammasome is 455 
attenuated in bone marrow derived macrophages (BMDMs) from HOIL-1L
-/-
 mice. ASC 456 
was identified as a substrate for linear ubiquitinylation associated with inflammasome 457 
formation, although the roles of linearly ubiquitinylated ASC in inflammasome formation 458 






























































have not been addressed. Reduction of LUBAC levels affects the activation of the 459 
inflammasome, and the secretion of IL-1β in BMDMs of HOIL-1L
-/-
 mice is suppressed 460 
independently of NF-κB signaling (124). Of note, the RBR domain of HOIL-1L is required 461 
for the linear ubiquitinylation of ASC in addition to HOIP RBR, although the RBR domain 462 
of HOIL-1L is dispensable for the generation of linear ubiquitin chains (124). The proposed 463 
involvement of the RBR domain of HOIL-1L in NEMO ubiquitinylation (86) indicates that 464 
the HOIL-1L RBR may be required for ASC linear ubiquitinylation.  465 
 466 
d)-2 Inhibition of RIG-I signaling  467 
 468 
Retinoic acid-inducible gene-I (RIG-I) belongs to the RIG-I-like receptor (RLR) 469 
family among the PRRs, and serves as a cytoplasmic virus RNA sensor that facilitates 470 
innate antiviral responses through the upregulation of type I IFNs, IFN-α and IFN-β (122, 471 
125). Upon recognition of viral RNA, RIG-I is conjugated with K63-linked ubiquitin 472 
chains generated by TRIM25, which facilitates interaction with an adaptor protein, 473 
mitochondrial antiviral signaling protein (MAVS) through their CARD domains. 474 
Subsequently, RIG-I interacts with TRAF3 via the TRAF-interacting motifs (TIM) of 475 
MAVS, leading to the recruitment of NF-κB signaling related-proteins including NEMO 476 
and IKK-dependent NF-κB activation (126). Unlike other PRR-mediated signaling 477 
mechanisms, LUBAC-mediated linear ubiquitinylation negatively regulates 478 






























































RIG-I-mediated signaling (127). NEMO conjugated with linear ubiquitin chains, but not 479 
unmodified NEMO, interacts with TRAF3, which interferes with the assembly of the 480 
MAVS-TRAF3 complex and eventually inhibits anti-virus IFN secretion (127). Consistent 481 
with this concept, the MEFs of SHARPIN-deficient cpdm mice show increased IFN 482 
mediated antiviral responses when infected with vesicular stomatitis virus (VSV), which is 483 
a negative-strand RNA virus (128). Another report suggested that HOIL-1L and HOIP 484 
suppress RIG-I signaling induced by Sendai viruses through the inhibition of 485 
RIG-I-TRIM25 interaction, which is mainly mediated by TRIM25 degradation in 486 
HOIL-1L
-/-
 MEFs with suppressed HOIP expression. In this scenario, TRIM25 is identified 487 
as a LUBAC substrate (129). The linear ubiquitin chain may function as a degradation 488 
signal, albeit weak (27, 130); however, further investigation is necessary to identify the role 489 
of LUBAC in RIG-I signaling.  490 
 491 
Analysis of the pathophysiological roles of linear ubiquitinylation using LUBAC 492 
mutant mice 493 
 494 
The phenotypes of mice lacking components of LUBAC are drastically diverse 495 
because of differences in the residual amount of functional LUBAC mainly. No LUBAC 496 
complex or linear ubiquitinylation activity is observed in HOIP
-/-
 mice. No linear 497 
ubiquitinylation activity can be detected in mice expressing C-terminal deleted HOIP or a 498 






























































ubiquitin binding deficient HOIP mutant in HOIP null mice despite the presence of the 499 
LUBAC complex. Mice lacking HOIL-1L (HOIL-1L
-/-
) or SHARPIN (cpdm) express a 500 
LUBAC complex composed of the other two subunits, although the amount of residual 501 
LUBAC is drastically reduced because of the destabilization of LUBAC provoked by the 502 
loss of one subunit. The linear ubiquitinylation activity is reduced but present in mice 503 
lacking SHARPIN or HOIL-1L. In addition, SHARPIN or HOIL-1L that does not form a 504 
complex with HOIP exists in cells. Indeed, LUBAC independent functions of SHARPIN or 505 
HOIL-1L were reported. SHARPIN controls lymphocyte migration via direct interaction 506 
with β1-integrin or lymphocyte-function-associated antigen-1 (LFA-1) (131, 132). 507 
HOIL-1L targets protein kinase C ζ for degradation under hypoxic conditions to promote 508 
tumor survival (133). Therefore, results obtained using HOIL-1L
-/-
 or cpdm mice, which are 509 
not linear chain null mice, need to be interpreted with caution.  510 
 511 
a) Mechanism underlying cpdm pathology 512 
 513 
SHARPIN-deficient cpdm mice and HOIL-1L
-/-
 mice are both defective in 514 
NF-κB activation because of instability of the LUBAC complex. Suppressed NF-κB 515 
activation is characterized by delayed phosphorylation of IκBα and decreased expression of 516 
NF-κB-targeting genes in response to TNF-α stimulation in both types of mutant mice (25, 517 
26). Nevertheless, cpdm mice, but not HOIL-1L
-/-
 mice, develop chronic dermatitis as 518 






























































described above (29). TNF-α signaling plays a role in the pathogenesis of cpdm, as 519 
intercrossing cpdm mice with TNF-α null mice ameliorates chronic dermatitis (35). The 520 
main functions of LUBAC-mediated linear ubiquitinylation are its contribution to canonical 521 
NF-κB activation and cell death regulation. NF-κB activation is suppressed in both cpdm 522 
and HOIL-1L
-/-
 mice at comparable levels (25, 26). MEFs from cpdm mice are more 523 
sensitive to TNF-α-induced cell death than those from HOIL-1L
-/-
 mice despite the fact that 524 
TNF-α-induced cell death is strongly induced in HOIL-1L
-/-
 cells (25). TNF-α induces two 525 
types of programmed cell death, apoptosis and necroptosis, and the latter is more prone to 526 
induce inflammation than the former (134, 135). To investigate the role of necroptosis and 527 
apoptosis in cpdm pathology, cpdm mice are crossed with mice lacking molecules involved 528 
in these two types of programmed cell death. Deletion of RIP3 or mixed lineage kinase 529 
domain-like protein (MLKL), which are both involved in necroptosis, only partially 530 
ameliorates cpdm symptoms (109, 110). Caspase 8 or FADD is involved in the induction of 531 
apoptosis. However, their deletion promotes necroptosis. Deficiency of caspase 8 or FADD 532 
specifically in keratinocytes combined with RIP3 ameliorated cpdm symptoms almost 533 
completely (109, 110). Moreover, crossing cpdm mice with mice expressing 534 
kinase-negative RIP1, which impairs necroptosis and certain forms of apoptosis, cured 535 
cpdm dermatitis completely (64). Thus, both apoptosis and necroptosis are involved in 536 
cpdm pathology.  537 
A recent report showed that the Rnf31 gene, which encodes HOIP, is located 538 






























































between the Psme2 and Irf9 genes, both of which are induced by interferon-γ (IFN-γ). In 539 
addition, the Rnf31 gene was shown to have an IFN regulatory factor 1 and two 540 
IFN-γ-responsive regulatory elements on the upstream and downstream regions of the 541 
genes, respectively (136). As expected, mRNA transcription of HOIP was increased after 542 
IFN-γ treatment. Increased protein levels of both HOIL-1L and SHARPIN in addition to  543 
HOIP were observed in MEFs, BMDMs, and primary keratinocytes in response to type I 544 
and type II IFN, which are induced mainly by immune cells including activated 545 
lymphocytes after RNA or DNA virus infection leading to enhanced activation of NF-κB 546 
(136). Moreover, intradermal injection of type I or type II IFN ameliorated cpdm dermatitis 547 
by upregulating HOIP expression in the skin, indicating that reduction of residual LUBAC 548 
underlies cpdm pathology. Therefore, attenuated NF-κB activation may also underlie cpdm 549 
pathology although NF-κB is known as a proinflammatory transcription factor (137). It is, 550 
thus, of interest to determine the phenotype of mice with further reduction of LUBAC 551 
composed of SHARPIN and HOIP in HOIL-1L
-/-
 mice. 552 
 553 
b) Investigating the role of LUBAC-mediated linear ubiquitinylation in B lymphocytes 554 
 555 
To dissect the functions of linear ubiquitin chains, it is indispensable to use mice 556 
lacking HOIP or the linear ubiquitinylation activity of HOIP. However, complete loss of the 557 
linear ubiquitinylation activity of LUBAC is associated with embryonic lethality. Therefore, 558 






























































the roles of linear ubiquitin chains in the immune system should be probed using tissue or 559 
cell type specific deletion of LUBAC ligase activity. Mice lacking the C-terminal part of 560 
HOIP, which contains the catalytic center for linear ubiquitinylation (B-HOIP ∆linear mice), 561 
were used to investigate the roles of LUBAC-mediated linear ubiquitinylation in B 562 
lymphocytes (54). The development of conventional B cells, both follicular and marginal B 563 
cells, was not affected by the loss of linear ubiquitinylation activity of LUBAC. However, 564 
the effector functions of B cells were heavily affected, with almost complete suppression of 565 
responses to thymus-dependent antigen and thymus-independent antigen II. Moreover, 566 
differentiation of B1 cells, which reside in the peritoneum, was heavily impaired by the loss 567 
of LUBAC ligase activity, and the serum titers of all subclasses of antibodies in resting 568 
stages were suppressed. These results indicated that the linear polyubiquitinylation activity 569 
of LUBAC plays crucial roles in B cells. Biochemical analyses revealed that canonical 570 
NF-κB and ERK activation mediated by the TNFR family receptors CD40 and 571 
transmembrane activator and CAML interactor (TACI) is attenuated in B cells from B-HOIP 572 
∆linear mice. CD40-induced JNK or alternative NF-κB activation is not overtly affected in 573 
HOIP ∆linear B cells. Activation of canonical NF-κB and ERK by TLR4 and TLR9 is also 574 
attenuated albeit less significant that that mediated by CD40. In this study, BCR-mediated 575 
signaling, which plays an important role in B1 cell development (138), was not affected by 576 
the loss of linear ubiquitinylation activity. These results suggest that receptors other than 577 
BCR play a role in B1-cell development through the activation of the canonical NF-κB 578 






























































pathway. However, the involvement of LUBAC in BCR-mediated canonical NF-κB 579 
activation via a ligase-independent mechanism was suggested in another study (139).  580 
 581 
Loss of HOIL-1L in patients and mice 582 
 583 
Patients with bi-allelic mutations in HOIL-1L genes have been reported (31, 140, 584 
141). Fibroblast cells from these patients decreased protein levels of the other LUBAC 585 
components, HOIP and SHARPIN, and impaired TNF-α and IL-1β induced NF-κB 586 
activation. In one study, chronic hyperinflammation, invasive bacterial infections associated 587 
with mild immunodeficiency, cardiomyopathy, and muscular amylopectinosis were 588 
detected in three patients, whereas the remaining 13 showed cardiomyopathy and muscular 589 
amylopectinosis, but no immunological symptoms (31).  590 
HOIL-1L
-/-
 mice do not show any overt phenotypes under pathogen-free 591 
conditions, although deposition of amylopectin-like materials could be observed in the 592 
aging heart (142). On the other hand, HOIL-1L
-/-
 mice are susceptible to acute infections by 593 
several pathogens including Listeria monocytogenes, indicating that HOIL-1L
-/-
 mice are 594 
immunodeficient (142). HOIL-1L
-/-
 mice are resistant to chronic infection by murine 595 
γ-herpesvirus 68 (MHV68), suggesting that chronic herpesvirus infection generates signs of 596 
auto-inflammation. These results imply that the lack of immunological symptoms in 597 
HOIL-1L
-/-
 mice is due to the pathogen-free conditions.   598 































































LUBAC in diseases  600 
 601 
In addition to the role of mutations in HOIL-1L genes, the involvement of 602 
LUBAC-mediated linear ubiquitinylation in disease was revealed recently. Aberrant NF-κB 603 
activation plays a critical role in the oncogenesis of activated B-cell-like diffuse large 604 
B-cell lymphomas (ABC DLBCL) (139). Yang et al. reported that SHARPIN and HOIP are 605 
essential for the growth of ABC DLBCL cells but not germinal center B-cell-like (GCB) 606 
DLBCL cells through the suppression of NF-κB activation. They also showed that two rare 607 
SNPs of the HOIP gene are highly enriched in ABC DLBCL (139). Mutations of the A20 608 
DUB that abrogate linear ubiquitin binding activity of the protein were reported in Hodgkin 609 
and non-Hodgkin B-cell lymphomas (92). Attenuated LUBAC expression suppresses lung 610 
metastases of osteosarcomas in mice (143). Moreover, downregulation of HOIP or 611 
SHARPIN expression promoted apoptosis induced by platinum-based genotoxins, 612 
including cisplatin and carboplatin, which are widely used anti-cancer drugs (144). Thus, 613 
LUBAC activity might be a suitable target to control malignant tumors. Gliotoxin, a major 614 
virulence factor of the opportunistic pathogen Aspergillus fumigatus, was recently 615 
identified as a specific inhibitor of LUBAC-mediated linear ubiquitinylation (145), which 616 
highlights the crucial roles of linear ubiquitinylation in the protection from infectious agents 617 
and the possibility of isolating LUBAC inhibitors from natural products. 618 































































Concluding remarks 620 
 621 
The present short article introduces the roles of the recently identified ubiquitin 622 
modification, linear ubiquitinylation, in the immune system. Linear polyubiquitin chains 623 
and LUBAC were identified in 2006 during analyses aimed at elucidating the molecular 624 
mechanism underlying the generation of polyubiquitin chains (27). To date, linear 625 
ubiquitinylation has been shown to play a role in inflammation, immune responses, and 626 
oncogenesis, as expected from its involvement in NF-κB activation. Inhibitors of 627 
LUBAC-mediated linear ubiquitinylation were suggested as suitable candidates for the 628 
treatment of malignant tumors. In addition, the finding that the ubiquitin ligase activity of 629 
LUBAC is induced by type I and type II IFNs implies a novel connection between the IFN 630 
and NF-κB pathways. The fact that phosphorylation of a Tyr residue in OTULIN, a linear 631 
chain specific DUB, suppresses the interaction between OTULIN and LUBAC, indicates 632 
crosstalk between Tyr phosphorylation and NF-κB activation. Thus, the roles of linear 633 
ubiquitinylation might not be limited to NF-κB activation or cell death regulation. In 634 
addition to NEMO and A20, proteins containing linear chain specific UBDs were reported. 635 
For example, the UBAN motif of Optineurin, which is a product of a mutated gene in 636 
glaucoma and amyotrophic lateral sclerosis, can recognize linear di-ubiquitin (146-148). 637 
Moreover, Optineurin is an autophagy receptor involved in the autophagic clearance of 638 






























































cytosolic Salmonella (146). The study of linear ubiquitin chains is just beginning. Further 639 
analyses may reveal additional unexpected roles of linear ubiquitin chains in the near 640 
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Figure legends  1032 
 1033 
Figure 1. The ubiquitin conjugating system and ubiquitin chain lineage-specific 1034 
behavior. 1035 
Ubiquitinylation is an enzymatic process mediated by a ubiquitin activating enzyme (E1), a 1036 
ubiquitin conjugating enzyme (ubiquitin carrier protein) (E2), and a ubiquitin ligase (E3). 1037 
First, ubiquitin is ATP-dependently transferred to E1 via formation of a thioester bond 1038 
between the C-terminal carboxyl group of ubiquitin and the cysteine residue in the active 1039 
site of E1. Ubiquitin on the E1 is then transferred to the cysteine residue of E2, which also 1040 
forms a thioester bond. Finally, E3 associates with the ubiquitin-bound E2 and a substrate, 1041 
and catalyzes the conjugation of ubiquitin to the substrate via an isopeptide bond between 1042 
the ε-amino group of a lysine residue of the substrate and the C-terminal carboxyl group of 1043 
ubiquitin. There are three classes of E3s: HECT, RING, and RBR E3s. HECT and RBR E3s 1044 
bind to ubiquitin before conjugating ubiquitin to substrates, as described in Figure 3. Once 1045 
the first ubiquitin is conjugated to the substrate, additional ubiquitins are conjugated 1046 
successively onto the terminal ubiquitin on the substrate to form polyubiquitin chains. 1047 
Polyubiquitin chains are generated by isopeptide bond formation between the C-terminal 1048 
carboxyl group of one ubiquitin and an ε-amino group of one of seven Lys (K) residues in 1049 
another ubiquitin molecule, thus generating seven types (K6, K11, K27, K29, K33 aK48, 1050 
and K63) of linkages. A linear (M1) linkage, in which the C-terminal carboxyl group of one 1051 






























































ubiquitin forms a peptide bond with an α-amino group of the N-terminal Met (M) residue 1052 
of another ubiquitin, was reported. Four types of polyubiquitin chains [K11-linked, 1053 
K48-linked, K63-linked, and Linear (M1-linked)] are shown. Each chain is recognized by 1054 
ubiquitin binding proteins containing a specific ubiquitin binding domain (UBD). The 1055 
polyubiquitin chains are cleaved by deubiquitinating enzymes (DUB). DUBs can be 1056 
specific for certain types of ubiquitin linkage. Ubiquitin monomers newly-trimmed by 1057 
DUBs are integrated into the ubiquitin pool to be used for further ubiquitination of other 1058 
proteins.  1059 
 1060 
Figure 2. Schematic representation of LUBAC components. 1061 
The linear ubiquitin chain assembly complex (LUBAC) is composed of heme-oxidized 1062 
IRP2 ligase 1L (HOIL-1L), HOIL-1 interacting protein (HOIP), and SH3 and multiple 1063 
ankyrin-repeat domains protein (SHANK)-associated RBCK1 homology (RH) 1064 
domain-interacting protein (SHARPIN). Arrows indicate protein-protein interactions to 1065 
form LUBAC’s ternary structure. Interactions between the HOIP NZF2 and SHARPIN 1066 
UBL are also involved in LUBAC formation; however, HOIP lacking NZF2, and not UBA, 1067 
binds to SHARPIN in cells. HOIP contains the catalytic center for ubiquitin E3 ligase 1068 
activity in its carboxyl-terminal region. UBL, ubiquitin-like domain; UBA, 1069 
ubiquitin-associated domain; NZF, nuclear protein localization 4(Npl4)-type zinc finger; 1070 
RING, really interesting new gene; IBR, in-between-RING domain; ZF, zinc finger; PUB, 1071 






























































peptide N-glycosidase (PNGase)/ubiquitin-associated domain; LDD, linear ubiquitin chain 1072 
determining domain. 1073 
 1074 
Figure 3. Different ubiquitin conjugation modes mediated by three E3 ligase families.  1075 
A. Homology to E6-AP C-terminus (HECT) E3 ligases forms an intermediate complex via 1076 
a thioester bond between a cysteine residue of E3s and the C-terminus of ubiquitin 1077 
activated by E2 before transfer to the substrate. B. Really Interesting New Gene (RING) E3 1078 
ligases catalyze the conjugation of ubiquitin from E2 to the substrate directly. C. The 1079 
RING-In-Between-RING (IBR)-RING (RBR) E3 ligase family, to which LUBAC belongs, 1080 
uses the hybrid ubiquitin conjugation mechanism of the RING and the HECT E3s. In this 1081 
mechanism, the RING2 domain of RBR E3s binds to the C-terminus of ubiquitin to form 1082 
an intermediate, as seen in a RING-like manner after the binding of ubiquitin-conjugated 1083 
E2 to the RING1 domain of the RBR E3s. The activated ubiquitin on the RING2 domain is 1084 
subsequently transferred to a substrate in a HECT-like manner.  1085 
 1086 
Figure 4. LUBAC-mediated linear ubiquitinylation in the canonical NF-κB activation 1087 
pathway. 1088 
The contribution of LUBAC to the tumor necrosis factor (TNF)-α-induced activation of 1089 
nuclear factor-kappa B (NF-κB) pathway is well-established. TNF-α engagement to TNF 1090 
receptor 1 (TNFR1) allows its conformational change resulting in the recruitment of RIP1 1091 






























































and TRADD via homotypic interactions between two death domains; TRAF2 and cellular 1092 
inhibitor of apoptosis proteins (cIAPs) are also incorporated into the TNFR1 complex. 1093 
RIP1 is often detected as a ubiquitin-conjugated protein after TNF-α stimulation. The E3 1094 
ligases, cIAPs, ubiquitinate components of the activated TNFR1 complex, including RIP1, 1095 
with K63 and K11-linked ubiquitin chains, and themselves by auto-ubiquitination. These 1096 
generated ubiquitin chains on components of the TNFR1 complex were suggested to serve 1097 
as a platform to recruit the TAK1 complex, which is composed of TAK1, TAB1, and TAB2 1098 
and/or TAB3, and the recruitment of TAK1 facilitates the phosphorylation of IKK2 1099 
necessary for the activation of the IKK complex. LUBAC is recruited to the ubiquitin 1100 
chains within the TNFR1 complex via the K63 (possibly also K11) ubiquitin chain-binding 1101 
property of the NZF1 domain of HOIP. The HOIP NZF1 domain can interact with NEMO 1102 
in the IKK complex in addition to ubiquitin chains, and conjugate the linear ubiquitin chain 1103 
on NEMO. The linear ubiquitin chain conjugated to NEMO recruits another IKK complex 1104 
because NEMO contains a specific binding region for linear ubiquitin chains called the 1105 
ubiquitin binding in ABIN and NEMO (UBAN) motif, which triggers dimerization of IKK 1106 
complexes and subsequent trans-autophosphorylation of IKK2. The activated IKK complex 1107 
phosphorylates IκBα, leading to its K48-linked ubiquitination and proteasomal degradation. 1108 
This process activates the cytosolic NF-κB transcription factor, facilitating its translocation 1109 
to the nucleus and the induction of the expression of target genes. 1110 
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Figure 5. Inhibition of TNF-α mediated cell death by linear ubiquitinylation 1112 
Upon binding TNF-α, TNFR1 interacts with TRADD, RIP1, TRAF2, and cIAP1 and 2 to 1113 
form complex I. LUBAC is also recruited to the activated TNFR1 complex via recognition 1114 
of ubiquitin chains in the TNFR1 complex possibly by cIAP1 and 2. LUBAC protects cells 1115 
from death by inducing the expression of various NF-κB target genes, including Bcl-2 and 1116 
cFLIP. In addition to the induction of anti-apoptotic genes, LUBAC inhibits 1117 
TNF-α-mediated cell death by a different mechanism, the inhibition of complex II. The 1118 
transition from complex I to complex II triggers cell death. TNFR1 induces two types of 1119 
programmed cell death, apoptosis and necroptosis, and formation of complex II, which is 1120 
composed of TRADD, FADD, caspase 8, RIP1, and possibly RIP3, precedes both types of 1121 
cell death. After the formation of complex II, caspase 8 is activated by dimerization and 1122 
digests RIP1 and RIP3, leading to apoptosis. When caspase 8 is inactivated, RIP1 and RIP3 1123 
kinases are activated and trigger necroptosis. The linear ubiquitination activity of LUBAC 1124 
is involved in the suppression of complex II formation, although the linear ubiquitinylation 1125 
substrates involved in the inhibition of complex II formation have not been convincingly 1126 
identified to date. 1127 

































































Figure 1. The ubiquitin conjugating system and ubiquitin chain lineage-specific behavior.  
Ubiquitinylation is an enzymatic process mediated by a ubiquitin activating enzyme (E1), a ubiquitin 
conjugating enzyme (ubiquitin carrier protein) (E2), and a ubiquitin ligase (E3). First, ubiquitin is ATP-
dependently transferred to E1 via formation of a thioester bond between the C-terminal carboxyl group of 
ubiquitin and the cysteine residue in the active site of E1. Ubiquitin on the E1 is then transferred to the 
cysteine residue of E2, which also forms a thioester bond. Finally, E3 associates with the ubiquitin-bound E2 
and a substrate, and catalyzes the conjugation of ubiquitin to the substrate via an isopeptide bond between 
the ε-amino group of a lysine residue of the substrate and the C-terminal carboxyl group of ubiquitin. There 
are three classes of E3s: HECT, RING, and RBR E3s. HECT and RBR E3s bind to ubiquitin before conjugating 
ubiquitin to substrates, as described in Figure 3. Once the first ubiquitin is conjugated to the substrate, 
additional ubiquitins are conjugated successively onto the terminal ubiquitin on the substrate to form 
polyubiquitin chains. Polyubiquitin chains are generated by isopeptide bond formation between the C-
terminal carboxyl group of one ubiquitin and an ε-amino group of one of seven Lys (K) residues in another 
ubiquitin molecule, thus generating seven types (K6, K11, K27, K29, K33 aK48, and K63) of linkages. A 
linear (M1) linkage, in which the C-terminal carboxyl group of one ubiquitin forms a peptide bond with an α-
amino group of the N-terminal Met (M) residue of another ubiquitin, was reported. Four types of 
polyubiquitin chains [K11-linked, K48-linked, K63-linked, and Linear (M1-linked)] are shown. Each chain is 
recognized by ubiquitin binding proteins containing a specific ubiquitin binding domain (UBD). The 
polyubiquitin chains are cleaved by deubiquitinating enzymes (DUB). DUBs can be specific for certain types 
of ubiquitin linkage. Ubiquitin monomers newly-trimmed by DUBs are integrated into the ubiquitin pool to be 
used for further ubiquitination of other proteins.  
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Figure 2. Schematic representation of LUBAC components.  
The linear ubiquitin chain assembly complex (LUBAC) is composed of heme-oxidized IRP2 ligase 1L (HOIL-
1L), HOIL-1 interacting protein (HOIP), and SH3 and multiple ankyrin-repeat domains protein (SHANK)-
associated RBCK1 homology (RH) domain-interacting protein (SHARPIN). Arrows indicate protein-protein 
interactions to form LUBAC’s ternary structure. Interactions between the HOIP NZF2 and SHARPIN UBL are 
also involved in LUBAC formation; however, HOIP lacking NZF2, and not UBA, binds to SHARPIN in cells. 
HOIP contains the catalytic center for ubiquitin E3 ligase activity in its carboxyl-terminal region. UBL, 
ubiquitin-like domain; UBA, ubiquitin-associated domain; NZF, nuclear protein localization 4(Npl4)-type zinc 
finger; RING, really interesting new gene; IBR, in-between-RING domain; ZF, zinc finger; PUB, peptide N-
glycosidase (PNGase)/ubiquitin-associated domain; LDD, linear ubiquitin chain determining domain.  
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Figure 3. Different ubiquitin conjugation modes mediated by three E3 ligase families.  
A. Homology to E6-AP C-terminus (HECT) E3 ligases forms an intermediate complex via a thioester bond 
between a cysteine residue of E3s and the C-terminus of ubiquitin activated by E2 before transfer to the 
substrate. B. Really Interesting New Gene (RING) E3 ligases catalyze the conjugation of ubiquitin from E2 to 
the substrate directly. C. The RING-In-Between-RING (IBR)-RING (RBR) E3 ligase family, to which LUBAC 
belongs, uses the hybrid ubiquitin conjugation mechanism of the RING and the HECT E3s. In this 
mechanism, the RING2 domain of RBR E3s binds to the C-terminus of ubiquitin to form an intermediate, as 
seen in a RING-like manner after the binding of ubiquitin-conjugated E2 to the RING1 domain of the RBR 
E3s. The activated ubiquitin on the RING2 domain is subsequently transferred to a substrate in a HECT-like 
manner.  
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Figure 4. LUBAC-mediated linear ubiquitinylation in the canonical NF-κB activation pathway.  
The contribution of LUBAC to the tumor necrosis factor (TNF)-α-induced activation of nuclear factor-kappa B 
(NF-κB) pathway is well-established. TNF-α engagement to TNF receptor 1 (TNFR1) allows its conformational 
change resulting in the recruitment of RIP1 and TRADD via homotypic interactions between two death 
domains; TRAF2 and cellular inhibitor of apoptosis proteins (cIAPs) are also incorporated into the TNFR1 
complex. RIP1 is often detected as a ubiquitin-conjugated protein after TNF-α stimulation. The E3 ligases, 
cIAPs, ubiquitinate components of the activated TNFR1 complex, including RIP1, with K63 and K11-linked 
ubiquitin chains, and themselves by auto-ubiquitination. These generated ubiquitin chains on components of 
the TNFR1 complex were suggested to serve as a platform to recruit the TAK1 complex, which is composed 
of TAK1, TAB1, and TAB2 and/or TAB3, and the recruitment of TAK1 facilitates the phosphorylation of IKK2 
necessary for the activation of the IKK complex. LUBAC is recruited to the ubiquitin chains within the TNFR1 
complex via the K63 (possibly also K11) ubiquitin chain-binding property of the NZF1 domain of HOIP. The 
HOIP NZF1 domain can interact with NEMO in the IKK complex in addition to ubiquitin chains, and conjugate 
the linear ubiquitin chain on NEMO. The linear ubiquitin chain conjugated to NEMO recruits another IKK 
complex because NEMO contains a specific binding region for linear ubiquitin chains called the ubiquitin 
binding in ABIN and NEMO (UBAN) motif, which triggers dimerization of IKK complexes and subsequent 
trans-autophosphorylation of IKK2. The activated IKK complex phosphorylates IκBα, leading to its K48-
linked ubiquitination and proteasomal degradation. This process activates the cytosolic NF-κB transcription 
factor, facilitating its translocation to the nucleus and the induction of the expression of target genes.  
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Figure 5. Inhibition of TNF-α mediated cell death by linear ubiquitinylation  
Upon binding TNF-α, TNFR1 interacts with TRADD, RIP1, TRAF2, and cIAP1 and 2 to form complex I. LUBAC 
is also recruited to the activated TNFR1 complex via recognition of ubiquitin chains in the TNFR1 complex 
possibly by cIAP1 and 2. LUBAC protects cells from death by inducing the expression of various NF-κB target 
genes, including Bcl-2 and cFLIP. In addition to the induction of anti-apoptotic genes, LUBAC inhibits TNF-α-
mediated cell death by a different mechanism, the inhibition of complex II. The transition from complex I to 
complex II triggers cell death. TNFR1 induces two types of programmed cell death, apoptosis and 
necroptosis, and formation of complex II, which is composed of TRADD, FADD, caspase 8, RIP1, and 
possibly RIP3, precedes both types of cell death. After the formation of complex II, caspase 8 is activated by 
dimerization and digests RIP1 and RIP3, leading to apoptosis. When caspase 8 is inactivated, RIP1 and RIP3 
kinases are activated and trigger necroptosis. The linear ubiquitination activity of LUBAC is involved in the 
suppression of complex II formation, although the linear ubiquitinylation substrates involved in the inhibition 
of complex II formation have not been convincingly identified to date.  
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